AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

Arrowhead Pharmaceuticals... (ARWR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

20.98

-0.10 (-0.47%)

At close: Feb 20, 2025, 3:59 PM

20.96

-0.12%

After-hours: Feb 20, 2025, 04:00 PM EST

undefined% (undefined)

Bid	20.4
Market Cap	2.65B
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-5.15
PE Ratio (ttm)	-4.07
Forward PE	n/a
Analyst	Buy

Ask	21.66
Volume	838,331
Avg. Volume (20D)	2,083,928
Open	21.08
Previous Close	21.08
Day's Range	20.57 - 21.13
52-Week Range	17.05 - 36.72
Beta	undefined

About ARWR

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, which is in phase 2b and one phase 3 clinical trial to treat hypertriglyceridemia; ARO-ANG3 that is in P...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Dec 16, 1993

Employees 609

Stock Exchange NASDAQ

Ticker Symbol ARWR

Website https://arrowheadpharma.com

Full Company Profile

Analyst Forecast

According to 10 analyst ratings, the average rating for ARWR stock is "Buy." The 12-month stock price forecast is $34.5, which is an increase of 64.40% from the latest price.

Buy 60.00%

Hold 40.00%

Sell 0.00%

Stock Forecasts

Next Earnings Release

Arrowhead Pharmaceuticals Inc. is scheduled to release its earnings on May 8, 2025, during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

1 week ago

-5.17%

Arrowhead Pharmaceuticals shares are trading lower... Unlock content with Pro Subscription

2 months ago

+24.23%

Arrowhead Pharmaceuticals shares are trading higher. Chardan Capital maintained a Buy rating on the stock.

News

1 day ago · seekingalpha.com

Arrowhead Pharmaceuticals: Progress During Adverse Market Conditions

Arrowhead Pharmaceuticals is executing on the clinical and regulatory side during adverse market conditions for biotech companies and genetic stocks in particular. Zodasiran is back in the clinic with...

1 week ago · seekingalpha.com

Arrowhead Pharmaceuticals, Inc. (ARWR) Q1 2025 Earnings Call Transcript

Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR ) Q1 2025 Earnings Conference Call February 10, 2025 4:30 PM ET Company Participants Chris Anzalone - President & CEO Bruce Given - Interim Chief Medical S...

1 week ago · businesswire.com

Arrowhead Pharmaceuticals Reports Fiscal 2025 First Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced financial results for its fiscal 2025 first quarter ended December 31, 2024. The Company is ...

1 week ago · businesswire.com

Arrowhead Pharmaceuticals Announces Closing of Global License and Collaboration Agreement with Sarepta Therapeutics

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the global licensing and collaboration agreement with Sarepta Therapeutics (NASDAQ: SRP...

4 weeks ago · businesswire.com

Arrowhead Pharmaceuticals to Webcast Fiscal 2025 First Quarter Results

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it will host a webcast and conference call on February 10, 2025, at 4:30 p.m. ET to dis...

1 month ago · businesswire.com

Arrowhead Pharmaceuticals Announces Acceptance of New Drug Application by U.S. FDA of Plozasiran for the Treatment of Familial Chylomicronemia Syndrome

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that the U.S. Food and Drug Administration (FDA) has accepted the New Drug Application (NDA)...

1 month ago · https://thefly.com

Sarepta's Elevidys launch remains strong with solid beat, says JPMorgan

Sarepta + Arrowhead +0.18 (+0.97%)

1 month ago · businesswire.com

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that it has dosed the first subjects in a Phase 1/2a clinical trial of ARO-INHBE, the compan...

2 months ago · businesswire.com

Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced that as an inducement to entering into employment with the Company, on December 13, 2024, th...

2 months ago · businesswire.com

Arrowhead Pharmaceuticals Presents Interim Clinical Data on ARO-CFB for the Treatment of Complement Mediated Diseases

PASADENA, Calif.--(BUSINESS WIRE)---- $arwr--Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) today announced interim results from a Phase 1/2a clinical study of ARO-CFB, the company's investigational R...

Load More News